ABL BIO INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26,400 KRW | +6.45% |
|
+14.53% | +7.32% |
ETFs positioned on ABL Bio Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.54% | - |
ABL Bio Inc. is a company mainly engaged in the development of biopharmaceuticals. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.32% | 919M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.75% | 22.18B | |
| -16.67% | 21.2B | |
| -8.68% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- A298380 Stock
- Funds and ETFs ABL Bio Inc.
